SAN DIEGO, June 1, 2011 /PRNewswire/ -- Ardea Biosciences,
Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, PharmD,
president and chief executive officer, will present at the
following upcoming investor conferences:
- Jefferies 2011 Global Healthcare Conference in New York, NY. Presentation: 10:00 a.m. EDT on Monday,
June 6, 2011.
- Wells Fargo Securities Healthcare Conference in Boston, MA. Presentation: 8:30 a.m. EDT on Wednesday, June 22, 2011.
About Ardea Biosciences, Inc.
Ardea Biosciences, Inc., of San Diego,
California, is a biotechnology company focused on the
development of small-molecule therapeutics for the treatment of
serious diseases. Lesinurad (RDEA594), our lead product candidate
for the treatment of hyperuricemia and gout, is a once-daily, oral
inhibitor of the URAT1 transporter. We have completed Phase
2b clinical studies of lesinurad and continue to advance the drug
in longer term extensions in preparation for Phase 3 development.
Our next-generation URAT1 inhibitor program is currently in
preclinical development. BAY 86-9766 (RDEA119) is a potent and
specific inhibitor of mitogen-activated ERK kinase (MEK) for the
treatment of cancer being developed under a global license
agreement with Bayer HealthCare. BAY 86-9766 is currently in a
Phase 2 study in patients with hepatocellular carcinoma in
combination with sorafenib and a Phase 1/Phase 2 study in patients
with advanced pancreatic cancer in combination with
gemcitabine.
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our plans and goals, the expected properties and benefits of
lesinurad, BAY 86-9766 (RDEA119) and our other
compounds and the timing and results of our preclinical, clinical
and other studies. Risks that contribute to the uncertain
nature of the forward-looking statements include risks related to
the outcome of preclinical and clinical studies, risks related to
regulatory approvals, delays in commencement of preclinical and
clinical studies, costs associated with our drug discovery and
development programs, and risks related to the outcome of our
business development activities, including collaboration or license
agreements. These and other risks and uncertainties are
described more fully in our most recently filed SEC documents,
including our Annual Report on Form 10-K and our Quarterly Reports
on Form 10-Q, under the headings "Risk Factors." All
forward-looking statements contained in this press release speak
only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were
made.
(Logo: http://photos.prnewswire.com/prnh/20091104/ARDEALOGO)
SOURCE Ardea Biosciences, Inc.